ACAD preview of OPK in Oct

I'm not here to promote ACAD, but as an investor in both ACAD and OPK (and TRXC for that matter) it will be interesting to see how a short squeeze may play out assuming a similar type of approval with the FDA in October for OPK.  ACAD on friday had their drug NUPLAZID™ (pimavanserin) -  Approved by the FDA for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis.  It stands alone by its unique treatment as does RAYALDEE®.  



Here are the key statistics for ACAD (per Yahoo):

Share Statistics

Avg Vol (3 month)3: 3,069,160

Avg Vol (10 day)3: 2,268,810

Shares Outstanding5: 112.64M

Float: 79.95M

% Held by Insiders1: 0.31%

% Held by Institutions1: 99.20%

Shares Short (as of Apr 15, 2016)3: 20.12M

Short Ratio (as of Apr 15, 2016)3: 4.42

Short % of Float (as of Apr 15, 2016)3: 24.06%

Shares Short (prior month)3: 18.75M



Here are the key statistics for OPK (per Yahoo)


Share Statistics

Avg Vol (3 month)3: 3,873,440

Avg Vol (10 day)3: 2,857,360

Shares Outstanding5: 545.84M

Float: 350.39M

% Held by Insiders1: 0.01%

% Held by Institutions1: 16.90%

Shares Short (as of Apr 15, 2016)3: 64.13M

Short Ratio (as of Apr 15, 2016)3: 13.41

Short % of Float (as of Apr 15, 2016)3: 21.20%

Shares Short (prior month)3: 66.97M


It should be interesting to see how this scenario plays out tomorrow morning and follow the trading pattern of ACAD as a possible preview of what we can expect to take place in October.